

Drug Injury Watch: Multaq Associated Lung Disease And Pulmonary Toxicity Pointed Out By New Safety Warnings In September 2012 Revised Label

Heart Drug Multaq Can Cause Pulmonary Fibrosis And Pneumonitis; Symptoms Are Inflammation Of The Lungs, Including Scarring And Thickening

(Posted by Tom Lamb at www.DrugInjuryWatch.com on September 12, 2012)

SUMMARY: In September 2012 the FDA approved more label changes for the safety-challenged heart drug Multaq (dronedarone), including one about certain types of interstitial lung disease such as pneumonitis and pulmonary fibrosis being serious side effects of Multaq use.

[\[Read this article in full at original source\]](#)

Earlier Multaq articles by attorney Tom Lamb on the Drug Injury Watch blog:

[Sanofi Heart Drug Multaq Found To Be Dangerous For Patients With Permanent Atrial Fibrillation](#)

[European Medicines Agency \(EMA\) Recommends Multaq Use Should Be Restricted For Safety Reasons](#)

[Multaq: August 2011 Update: Another Liver Failure Case Report Article In Medical Journal](#)

[Multaq Cardiovascular Deaths Overshadow Earlier Liver Injury Concerns For Drug Regulators](#)

[Sanofi Heart Medication Multaq Has Constantly Been On FDA's Radar During 2010 And 2011](#)

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
<http://www.DrugInjuryWatch.com>